These results suggested that TSE1 exhibited lower cytotoxicity to normal ovarian cells than to ovarian cancer cells, and its inhibitory activity on the platinum-resistant OVCAR-3 and A2780/CP70 cells was much stronger than cisplatin. Here, PRKAR1A is linked to ovarian carcinoma.